Jazz Pharmaceuticals plc (JAZZ), Wednesday announced a global license agreement with Denmark-based Saniona to obtain exclusive worldwide rights to develop SAN2355, a preclinical, selective small molecule activator for epilepsy treatment.
As per the deal, Saniona will receive an upfront payment of $42.5 million, development and regulatory milestone payments of upto $192.5 million, and commercial milestone payments of upto $800 million.
Following the deal, Jazz will lead and fund further development, regulatory submissions, and global commercialization activities regarding SAN2355.
In the pre-market hours, JAZZ is trading at $119.45, up 0.35 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.